January 18, 2019 11:21 AM ESTUpdated 11:34 AM

Tyme flops on cancer drug data; Lilly IND filing triggers $8M payment to partner Zymeworks

Natalie Grover

Reporter

→ Tyme Technologies on Friday touted “substantially improved survival benefit” from its experimental drug SM-88 in a single arm study in advanced pancreatic cancer patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tyme flops on cancer drug data; Lilly IND filing triggers $8M payment to partner Zymeworks

Natalie Grover

Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Tyme flops on can­cer drug da­ta; Lil­ly IND fil­ing trig­gers $8M pay­ment to part­ner Zymeworks

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Tyme flops on cancer drug data; Lilly IND filing triggers $8M payment to partner Zymeworks